Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Akero Therapeutics Inc

0K4
Current price
30.88 EUR -1.15 EUR (-3.56%)
Last closed 29.76 USD
ISIN US00973Y1082
Sector Healthcare
Industry Biotechnology
Exchange Frankfurt Exchange
Capitalization 2 404 582 400 USD
Yield for 12 month +94.53 %
1Y
3Y
5Y
10Y
15Y
0K4
21.11.2021 - 28.11.2021

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

45.78 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-29 000 USD

Last Year

-260 000 USD

Current Quarter

Last Quarter

-1 000 USD

Key Figures 0K4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -234 174 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -19.15 %
PEG Ratio
Return On Equity TTM -28.87 %
Wall Street Target Price 45.78 USD
Revenue TTM
Book Value 9.6 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -3.78 USD
Diluted Eps TTM -3.78 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 0K4

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 0K4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 0K4

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -6.7701
Price Book MRQ 3.2549

Financials 0K4

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 0K4

For 52 weeks

13.86 USD 37 USD
50 Day MA 29.02 USD
Shares Short Prior Month 6 766 665
200 Day MA 24.9 USD
Short Ratio 8.67
Shares Short 4 715 504
Short Percent 6.99 %